Massive liver cancer study aims to personalize treatment for 2000 patients

NCT ID NCT07156617

Not yet recruiting Knowledge-focused Sponsor: Xuhua Duan Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will analyze data from 2000 liver cancer patients to see how well interventional therapy combined with systemic drugs (like targeted therapy and immunotherapy) works in real life. Researchers will look at differences in outcomes and side effects, and use machine learning to predict risks. The goal is to help doctors tailor treatments to each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Interventional therapy (procedure) and systemic therapy (drugs like Lenvatinib, Apatinib, Camrelizumab, Tislelizumab)
What this could lead to: If successful, this could help doctors personalize liver cancer treatment by identifying which patients benefit most from combined therapy and predicting side effects.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary across patients and may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Deng zhou People's Hospital

Dengzhou, Henan, China
First People's Hospital of Shangqiu

Shangqiu, Henan, China
Huai He Hospital of Henan University

Kaifeng, Henan, China
Jiangxi Provincial People's Hospitail

Nanchang, Jiangxi, China
Luo Yang Central Hospital

Luoyang, Henan, China
Second People's Hospital of Jiaozuo

Jiaozuo, China
The First Affiliated Hospital of Henan University of science and Technology

Luoyang, Henan, China
The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China
The Second Affiliated Hospital of Hainan Medical Universsity

Haikou, Hainan, China
The Second People's Hospital of Jiaozuo

Jiaozuo, Henan, China
Wuxi No.5 People's Hospital

Wuxi, Jiangsu, China
Xingtai No.5 Hospital

Xingtai, Hebei, China
Zhou Kou Central Hospital

Zhoukou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.